Form 4: Entera Bio Director Sean Ellis Acquires Shares and Options in Lieu of Fees
SEC Form 4
Director Sean Ellis receives shares and options from Entera Bio in lieu of cash fees and as an annual grant.
Summary
- On January 15, 2025, Sean Ellis, a director of Entera Bio Ltd., acquired 7,100 ordinary shares in lieu of cash fees for services rendered as a director for the fourth quarter of 2024.
- The price per share was $0.
- Ellis also acquired 28,509 stock options as part of the Board's annual grant to directors, with an exercise price of $2.28.
- These options vest ratably on a quarterly basis over a one-year period commencing on January 1, 2025, and expire on January 15, 2035.
- Following these transactions, Ellis directly owns 28,509 derivative securities and 134,727 ordinary shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The director's acceptance of shares in lieu of cash and the option grant suggest confidence in the company's prospects. It's a routine transaction, but indicates alignment of interests.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.
- The grant of stock options aligns the director's interests with those of the shareholders, incentivizing value creation.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Director compensation through equity is a common practice in the biotech industry to align management interests with shareholder value. This is a standard method for compensating board members, especially in smaller companies.
Comparison to Industry Standards
- Equity compensation for board members is a common practice across the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options and restricted stock units as part of their director compensation packages.
- The vesting schedule of one year is fairly standard for director option grants.
Related Party Transactions
- The award of shares and options to Sean Ellis, a director, is a related party transaction.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the issuance of new shares and options, potentially diluting existing ownership.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Options vest ratably on a quarterly basis over a one-year period commencing on this date. |
| 01/15/2025 | Date of transaction for share and option acquisition. |
| 01/15/2035 | Expiration date of the stock options. |
| 01/17/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.